Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French Innovative Leukemia Organization (FILO)

Source: American Journal of Hematology - Category: Hematology Authors: Tags: Correspondence Source Type: research